Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and safety of G-CSF in combination with venetoclax and azacitidine (VAG) in treatment of patients with higher-risk Myelodysplastic Syndromes (MDS)

View Full Paper
Ask AI
Bookmark
Share

Authors

QXQingyu XuTSTing ShiWGWen Gao

Discussion

Loading...

Member takes

Overview

Retrospective evaluation of G-CSF plus venetoclax and azacitidine shows high response rates in higher-risk MDS, suggesting enhanced therapy potential.

Key Points

  • To assess the efficacy and safety of G-CSF combined with venetoclax and azacitidine in treating higher-risk MDS.
  • Retrospective evaluation of the VAG regimen in higher-risk MDS patients
  • Used IPSS-R scoring system to define higher-risk patients
  • Monitored treatment response using IWG 2023 criteria
  • 71% of patients achieved complete remission (CR)
  • 88% overall response rate with 9 out of 11 transfusion-dependent patients becoming transfusion-independent
  • All patients experienced treatment-emergent adverse events, primarily neutropenia and anemia

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d897https://doi.org/10.1182/blood-2025-5646
View Full Paper
Ask AI
Bookmark
Share